相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements
Mondher Toumi et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2017)
Linking the Price of Cancer Drug Treatments to Their Clinical Value
Lucia Gozzo et al.
CLINICAL DRUG INVESTIGATION (2016)
The cost and burden of cancer in the European Union 1995-2014
Bengt Jonsson et al.
EUROPEAN JOURNAL OF CANCER (2016)
Price, value, and the cost of cancer drugs
Tito Fojo et al.
LANCET ONCOLOGY (2016)
Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
Sabine Vogler et al.
LANCET ONCOLOGY (2016)
Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
Kim Pauwels et al.
FRONTIERS IN PHARMACOLOGY (2016)
From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-Span Approach to Bring New Drugs to Patients
H-G Eichler et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Do the Current Performance-Based Schemes in Italy Really Work? Success Fee: A Novel Measure for Cost-Containment of Drug Expenditure
Andrea Navarria et al.
VALUE IN HEALTH (2015)
Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
Alessandra Ferrario et al.
SOCIAL SCIENCE & MEDICINE (2015)
Market-access agreements for anti-cancer drugs
Katelijne van de Vooren et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2015)
Market access of cancer drugs in European countries: improving resource allocation
Kim Pauwels et al.
TARGETED ONCOLOGY (2014)
Sharing Risk between Payer and Provider by Leasing Health Technologies: An Affordable and Effective Reimbursement Strategy for Innovative Technologies?
Richard Edlin et al.
VALUE IN HEALTH (2014)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
Thomas Morel et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Differences in external price referencing in Europe-A descriptive overview
Christine Leopold et al.
HEALTH POLICY (2012)
Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals
Josh J. Carlson et al.
JOURNAL OF MANAGED CARE PHARMACY (2009)
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
Tito Fojo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Efficacy, safety, and cost of new anticancer drugs
S Garattini et al.
BMJ-BRITISH MEDICAL JOURNAL (2002)
分享论文
